A Leader in Scientific Breakthroughs
BrightFocus Foundation is a premier private funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. We are currently managing a nearly $75+ million global portfolio of more than 280 scientific projects.
Learn more about grants awarded in the most current fiscal year (nearly $25 million in funding for 95new awards in FY2022).
Clinical trial results released Nov. 29 for lecanemab, a drug targeting early Alzheimer’s disease, reported a moderate slowing of cognitive decline in patients by 25% through the removal of amyloid-beta (Aβ) in the brain.
Gael Chetelat, PhD, University of Caen-Normandy, France, was honored on Oct. 21, 2022, by Women’s Health Access Matters for her BrightFocus-funded project, “Sex Differences in Risk Profiles Across the Alzheimer’s Disease Continuum.”
More than 75 graduate students, postdoctoral fellows, and other early-career scientists from around the world participated in this year’s BrightFocus Alzheimer’s Fast Track, Nov. 9-11, 2022, in San Diego.